FDA expert wants Avandia withdrawn

The FDA's David Graham says that GSK's Avandia should be pulled from the market due to safety concerns. The safety expert made a presentation at today's committee hearing on the therapy that outlines the cardiovascular risks associated with Avandia while noting that the rival diabetes drug Actos does not raise risks. He topped that off by observing that Avandia has no unique short-term benefits and no demonstrated long-term benefits. It remains to be seen if another blow can knock Avandia out of the market--or if FDA officials will listen to what Graham has to say. Any new regulatory move against Avandia would be a big blow to Glaxo, which has seen the market for its blockbuster therapy wither as new reports come out illustrating health risks linked to the therapy.

- here's the article from The New York Times

Related Article:
Docs shunning Avandia in wake of safety study. Report
Researchers raise new warnings about Avandia. Report
Avandia risks exposed under deal to post data. Report
Diabetes expert issued harsh Avandia critique in 2000. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.